Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Pascal Vranckx

REGISTER for free or LOG IN to view this content

Become a GOLD or PLATINUM member to access PowerPoint files, presentation audio, and video

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

We Recommend